Catalent shells out $230m to expand US gene therapy plant

URLhttps://bioprocessintl.com/bioprocess-insider/faci
SourceBioprocess International
Date Published10/28/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Catalent, Inc.
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):700
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2022
Domestically, the work will be done:In-house
Capital investment ($):230
City reshored to:Harmans
State(s) reshored to:MD
If relevant, work nearshored to:-
Industry(ies):Chemicals
Product(s) reshoredviral vectors
What domestic positive factors made reshoring more attractive?Manufacturing/engineering joint innovation (R&D), Skilled workforce availability/training
Find Reshoring Articles